Financial Performance - Total revenue for the year ended December 31, 2025, was RMB 189,411,000, a decrease of 4.9% from RMB 199,342,000 in 2024[4] - Gross profit increased to RMB 77,711,000, up 8.9% from RMB 71,407,000 in the previous year[4] - The company reported a net loss of RMB 2,197,000 for the year, significantly improved from a loss of RMB 63,263,000 in 2024[4] - Basic and diluted earnings per share for the year were RMB 0.34, compared to a loss of RMB 11.11 per share in 2024[4] - The company reported a total loss before tax of RMB 65,257,000 for the year ending December 31, 2024, with significant contributions from unallocated expenses of RMB 25,798,000 and financial costs of RMB 584,000[23] - The pre-tax profit for 2025 was RMB 10,000, a recovery from a loss of RMB 65,257,000 in 2024[30] - The company reported a net profit of approximately RMB 1.9 million for 2025, compared to a net loss of approximately RMB 59.2 million in 2024, indicating a turnaround from loss to profit[39] - The total comprehensive loss for 2025 was approximately RMB 2.2 million, a significant improvement from a loss of RMB 63.3 million in 2024[76] Revenue Breakdown - For the year ending December 31, 2025, total revenue reached RMB 189,411,000, with medical beauty services contributing RMB 152,909,000, medical beauty equipment RMB 32,832,000, and consulting services RMB 3,670,000[24] - Revenue for the year ended December 31, 2025, was RMB 189,411 thousand, a decrease of 5.0% compared to RMB 199,342 thousand in 2024[49] - Revenue from medical beauty services in 2025 was approximately RMB 152.9 million, an increase of about 7.6% from RMB 142.1 million in 2024[60] - Revenue from minimally invasive beauty services in 2025 was approximately RMB 84.5 million, up about 23.4% from RMB 68.5 million in 2024, driven by an increase in active customers and average spending[60] - Revenue from skin beauty services in 2025 was approximately RMB 62.3 million, a decrease of about 8.4% from RMB 68.1 million in 2024, primarily due to a reduction in active customers[60] - Revenue from cosmetic surgery services in 2025 was approximately RMB 4.8 million, an increase from RMB 4.1 million in 2024[60] Expenses and Costs - Research and development expenses rose to RMB 2,070,000, an increase from RMB 717,000 in the previous year[4] - The cost of supplies consumed decreased to RMB 61,290,000 in 2025 from RMB 65,611,000 in 2024, suggesting improved cost efficiency[27] - Sales and distribution expenses in 2025 were approximately RMB 37.8 million, down about 20.8% from RMB 47.7 million in 2024, attributed to reduced market investments[72] - Administrative expenses decreased by approximately 25.1% to RMB 31.3 million in 2025, primarily due to a reduction in share-based payment expenses and intermediary service costs[73] - The financial cost for 2025 was approximately RMB 2.7 million, slightly down from RMB 2.8 million in 2024[74] Assets and Liabilities - Cash and cash equivalents increased to RMB 57,793,000, up from RMB 28,870,000 in 2024[5] - Total current liabilities amounted to RMB 125,755,000, slightly up from RMB 123,588,000 in 2024[5] - Non-current liabilities decreased significantly to RMB 13,638,000 from RMB 30,817,000 in the previous year[6] - The company's total assets less current liabilities stood at RMB 111,896,000, down from RMB 126,335,000 in 2024[5] - The company maintained a net asset value of RMB 98,258,000, an increase from RMB 95,518,000 in 2024[6] - The total liabilities as of December 31, 2025, were approximately RMB 139.4 million, down from RMB 154.4 million in 2024, resulting in a debt-to-equity ratio of approximately 141.8%[86] Shareholder Information - The company did not declare or pay any dividends for the year ended December 31, 2025[32] - The board has decided not to declare any final dividend for the fiscal year 2025, consistent with the previous year[106] - The average number of ordinary shares outstanding increased to 557,077,333 in 2025 from 532,837,181 in 2024, which may impact earnings per share calculations[33] Regulatory and Compliance - International Financial Reporting Standard (IFRS) 18 introduces new presentation requirements for income statements, categorizing all income and expenses into five categories: operating, investing, financing, income tax, and discontinued operations[11] - The amendments to IFRS 9 and IFRS 7 are expected to have no significant impact on the group's financial statements[14][15][16] - The company has established an audit committee to oversee financial reporting processes and compliance with legal regulations[112] - The company has adopted the corporate governance code to ensure transparency, accountability, and independence[109] Strategic Initiatives - The company plans to enhance the capacity of non-surgical medical beauty services, focusing on the introduction of new technologies and equipment to meet consumer demand[42] - The company aims to launch more products and services tailored to different skin types and age groups to meet personalized consumer needs[42] - The company is optimizing its sales channels by leveraging internet platforms, social media, and partnerships with third-party platforms to enhance market reach and operational efficiency[45] - The company plans to focus on the sales of non-surgical medical beauty devices, increasing investment in technology and research, and expanding the geographical coverage of medical beauty service institutions[105] Market Conditions - The medical beauty industry in China is still in a phase of expansion and adjustment, with non-surgical beauty services being the main growth driver, particularly anti-aging projects[105] - The company faces risks including medical liability insurance, brand recognition, and exchange rate fluctuations affecting its operations[53]
瑞丽医美(02135) - 2025 - 年度业绩